Figure 5
Figure 5. TCL165-79 peptide-specific T cells lysed human lymphoma cell lines and primary lymphoma cells. (A,C) Intracellular staining for TCL1 was performed on tumor cell lines and normal donor peripheral blood B cells (A) and primary human lymphoma cells (C). Black histograms represent cells stained with isotype control antibody, and open histograms represent staining with TCL1 antibody. (B,D) CD8+ T cells purified from TCL165-79 peptide-specific T cell lines by magnetic cell separation were incubated with tumor cell lines and normal peripheral blood B cells (B) or primary human lymphoma cells (D). A 4-hour 51Cr-release cytotoxicity assay was performed, and the percentage of specific lysis is shown. The HLA-A2 expression for each of the cell types is shown in the figures. Data in panels B and D are representative of 3 independent experiments.

TCL165-79 peptide-specific T cells lysed human lymphoma cell lines and primary lymphoma cells. (A,C) Intracellular staining for TCL1 was performed on tumor cell lines and normal donor peripheral blood B cells (A) and primary human lymphoma cells (C). Black histograms represent cells stained with isotype control antibody, and open histograms represent staining with TCL1 antibody. (B,D) CD8+ T cells purified from TCL165-79 peptide-specific T cell lines by magnetic cell separation were incubated with tumor cell lines and normal peripheral blood B cells (B) or primary human lymphoma cells (D). A 4-hour 51Cr-release cytotoxicity assay was performed, and the percentage of specific lysis is shown. The HLA-A2 expression for each of the cell types is shown in the figures. Data in panels B and D are representative of 3 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal